A Phase III Study of Interferon-Refractory Patients with BCR/ABL (+) Chronic Myelogenous Leukemia (CML) Treated with Homoharringtonine (NSC-141633) Vs. Hydroxurea

Diagnosis of chronic myelogenous leukemia (CML) in chronic phase with evidence of Ph+ or BCR/ABL+; no prior therapy with HHT; no more than 6 months cumulative (< 180 days) of prior HU therapy (however, patients may not have received more than 60 days of HU treatment after failing interferon). Patients with previous intolerance or failure to respond to HU are not eligible; must have failed an adequate trial (5 M units/m2/day) of IFN / Ara-C; patients with tachyarrhythmias are not eligible; female patients must be non-pregnant, non-nursing.